Strategies to Improve BCG Vaccine Efficacy

Bali, Prerna; Tousif, Sultan; Das, Gobardhan; Kaer, Luc Van

doi:10.2217/imt.15.60

Cited by 14 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This concentration has varied effects. The effects are varied according to the quantity of feasible to dead strains used in for one quantity (Bali et al, 2015). BCG vaccine shows excellent efficacy in Tuberculosis.…”

Section: The Vaccine For Tuberculosis Related To Hivmentioning

confidence: 99%

Strategies of Tuberculosis–HIV Vaccines Design using Immunoinformatic Approach

Fatonah

Wicaksono

Tambunan³

2019

OnLine Journal of Biological Sciences

View full text Add to dashboard Cite

Tuberculosis is amongst the highest cause death worldwide. According to WHO, an estimated of more than a million people fell ill with Tuberculosis (TB) in 2016. The resistances of the M. tuberculosis (MTb) bacteria make drugs, not that useful in battle with TB. Vaccination is a better choice to avoid the worst cases of TB. The resistance possessed by MTb bacteria with some of the drugs reported creates its challenge to reduce the high rate of TB related death. One of the concerns is the high mortality rate due to TB associated with HIV. However, there's still no effective vaccine for Tuberculosis-Human Immunodeficiency Virus (TB-HIV). Vaccines for Tuberculosis-HIV even on the way of progress to get the demanding the mutation of the bacteria and challenging scientists to get the right vaccines for this disease. Immunoinformatic is one of the approaches that can speed up the making of the vaccine.

show abstract

Section: The Vaccine For Tuberculosis Related To Hivmentioning

confidence: 99%

Strategies of Tuberculosis–HIV Vaccines Design using Immunoinformatic Approach

Fatonah

Wicaksono

Tambunan³

2019

OnLine Journal of Biological Sciences

View full text Add to dashboard Cite

show abstract

“…Unfortunately, BCG (bacillus Calmette-Guérin), the only vaccine widely used against TB, provides varied protective efficacy (0-80% in randomized control trials) (3)(4)(5). Recently, the emergence of drug-resistant Mtb stains as well as HIV-TB co-infection poses numerous complexities for TB control (6,7).…”

Section: Tuberculosis (Tb) a Worldwide Infectious Disease Caused Bymentioning

confidence: 99%

“…For immunotherapy, mice were infected intravenously via lateral caudal vein with 6.8x10 5 live Mtb strain H37Rv. At 4 weeks after infection, immunotherapy was applied and injection strategy was the same as immune responses evaluation listed above.…”

Section: Cytokines Assay 25x10mentioning

confidence: 99%

Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice

et al. 2018

View full text Add to dashboard Cite

Abstract. The emergence of drug-resistant tuberculosis (TB) and HIV-TB co-infection fuels an urgent need to develop novel therapeutic approaches, including therapeutic vaccines. Therapeutic vaccines have been proven to be a good strategy by inducing antigen specific immune responses against TB infection. In the present study, a recombinant plasmid based on lentiviral vector expressing fusion antigen Ag85B-Rv3425 (A3), and was constructed the immunogenicity and treatment effects in TB mice were assessed. The results showed that A3 delivered by the plasmid could be expressed appropriately in vivo and induced higher production of tumor necrosis factor-α and interleukin-2 compared with A3 recombinant protein in mice. Moreover, the recombinant plasmid expressing A3 confered resistance to acute TB infection in mice, characterized by a reduction in the bacterial load in the lungs and spleen, as well as attenuated TB lesions in lung tissues. These results implicated that the recombinant plasmid based on lentiviral vector expressing A3 is a potent and promising therapeutic agent to treat acute TB infection.

show abstract

“…BCG has subsequently come under much scrutiny. Each BCG vaccine dose, whilst containing a preparation of attenuated M. bovis, has different biological effects, as the amount of viable versus dead organisms in each dose varies (10).…”

Section: Introductionmentioning

confidence: 99%

“…BCG has efficacy ranging from 0 to 80% against adult pulmonary TB (10,11), providing protection for 10 to 20 years from immunisation. As a partially-effective vaccine, BCG only protects paediatric patients from severe TB.…”

Section: Introductionmentioning

confidence: 99%

In silico design of Mycobacterium tuberculosis epitope ensemble vaccines

Shah

Mistry

Reche

et al. 2018

Molecular Immunology

View full text Add to dashboard Cite

Effective control of Mycobacterium tuberculosis is a global necessity. In 2015, tuberculosis (TB) caused more deaths than HIV. Considering the increasing prevalence of multi-drug resistant forms of M. tuberculosis, the need for effective TB vaccines becomes imperative. Currently, the only licensed TB vaccine is Bacillus Calmette-Guérin (BCG). Yet, BCG has many drawbacks limiting its efficacy and applicability. We applied advanced computational procedures to derive a universal TB vaccine and one targeting East Africa. Our approach selects an optimal set of highly conserved, experimentally validated epitopes, with high projected population coverage (PPC). Through rigorous data analysis, five different potential vaccine combinations were selected each with PPC above 80% for East Africa and above 90% for the World. Two potential vaccines only contained CD8+ epitopes, while the others included both CD4+ and CD8+ epitopes. Our prime vaccine candidate was a putative seven-epitope ensemble comprising: SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, AAHKGLMNIALAISA, FPAGGSTGSL, MLLAVTVSL, QSSFYSDW and KMRCGAPRY, with a 97.4% global PPC and a 92.7% East African PPC.

show abstract

Strategies to Improve BCG Vaccine Efficacy

Cited by 14 publications

References 19 publications

Strategies of Tuberculosis–HIV Vaccines Design using Immunoinformatic Approach

Strategies of Tuberculosis–HIV Vaccines Design using Immunoinformatic Approach

Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice

In silico design of Mycobacterium tuberculosis epitope ensemble vaccines

Contact Info

Product

Resources

About